Derm-Biome’s DB-006 Demonstrates Superior Efficacy in Preclinical Atopic Dermatitis Study: Reduces Itch, Inflammation, and IgE Levels, Outperforms Leading Topical DrugsVANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc., a Vancouver-based biopharmaceutical company focused on skin health and longevity, today announced positive preclinical results for its novel small molecule, DB-006. The compound demonstrated high efficacy in treating atopic dermatitis (AD), significantly reducing key disease drivers, including pruritus (itch), epithelial thickening, inflammation, and immunoglobulin E (IgE) levels.
Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drugVANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that its topical drug DB-007-5 was highly effective at treating atopic dermatitis (AD) and is more potent at reducing itch than the current leading AD drug in a well-established preclinical model of human AD.
Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory BoardVANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company developing safe and highly effective topical treatments for inflammatory skin diseases and skin conditions, is pleased to announce that it has added acne and acne scarring expert Dr. Jerry Tan to its Scientific Advisory Board.
Derm-Biome Pharmaceuticals to develop skincare treatment that promotes skin health and longevityVANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy aging, is excited to announce the development of a novel, science-backed skincare treatment aimed at targeting some of the root causes of skin aging, such as chronic inflammation and cellular damage. Derm-Biome’s compounds exhibit a broad range of beneficial effects, including anti-inflammatory, antioxidant, and antimicrobial activities. In preclinical studies, topical application of Derm-Biome’s compounds has produced rapid and noticeable improvements to the appearance of skin.
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant fundingVANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to announce that, in partnership with TransBIOtech (Quebec), is being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the Natural Sciences and Engineering Council of Canada in collaboration with the Social Sciences and Humanities Research Council and the Canadian Institutes of Health Research.
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 million Americans a year developing this condition. Treating AKs before the cells become cancerous and spread to other parts of the body is crucial. For those patients with multiple AKs, common treatment options are chemotherapy creams and photodynamic therapy. Although effective, these treatments come with significant side effects, such as redness, blistering, and peeling, with recovery times that can be lengthy and uncomfortable. The global actinic keratosis treatment market size is projected to reach as high as $10 billion USD by 2031, fuelled by increasing cases of AK and rising healthcare spending.
Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseasesVANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin diseases and skin cancer, is pleased to announce that it will soon begin a GLP toxicology study for DB-007-4, a potential best-in-class, first line topical treatment for inflammatory skin diseases such as acne, atopic dermatitis (AD), and rosacea. Toxicology studies are an essential part of drug development as they help to evaluate the potential safety and toxicity of a drug candidate before it is tested on humans.
Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer StudyVANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver based biopharmaceutical company with a focus on skin disease, is excited to announce that it is collaborating with Dr. Anna Mandinova from the Department of Dermatology at Massachusetts General Hospital in a skin cancer study. Current standard of care chemotherapy-based creams damage normal skin, resulting in debilitating side effects that lead to poor patient compliance. Derm-Biome has developed a second-generation topical treatment for precancerous skin conditions (such as actinic keratosis) and non-melanoma skin cancers that is highly selective for cancer cells while being well-tolerated by normal skin. Soaring skin cancer rates are reaching all-time highs in many parts of the world, and there are now more global deaths from non-melanoma skin cancers than melanoma itself.
Derm-Biome Pharmaceuticals to Present at the 2023 OBIO Investment Summit on February 10, 2023VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health, is pleased to announce that it has been invited to present at the 2023 OBIO Investment Summit (OIS) in Toronto on Friday, February 10th at 11:51am EST. The Summit is Canada’s premier health science investment event, a forum that connects global investors with Canada’s best technology innovators. Since 2018 summit companies have raised $1.3 billion.
Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in AcneVANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health, is pleased to announce that in a preclinical trial run by the Dr. George Lui lab at the University of California San Diego (UCSD) School of Medicine, one of its topical lead compounds produced significant inhibitory effects in an animal model of acne, a common chronic inflammatory skin disease for which there is a significant unmet need.
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinicVANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has initiated a program aimed at advancing its topical treatments for precancerous skin conditions such as actinic keratosis and non-melanoma skin cancers such as squamous cell carcinoma through to the clinic. One in every three cancers diagnosed worldwide is skin cancer, with non-melanoma skin cancers the most common of all types of cancer, representing a significant market opportunity. According to a report by Grand View Research, Inc, the global actinic keratosis treatment market size alone is expected to reach $8.12 billion USD by 2028.
